financetom
Business
financetom
/
Business
/
Dynatrace Offers Valuation Increase Potential, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dynatrace Offers Valuation Increase Potential, Oppenheimer Says
Aug 27, 2025 8:07 AM

10:38 AM EDT, 08/27/2025 (MT Newswires) -- Dynatrace ( DT ) could see an increase in its valuation as the catalysts are in place, Oppenheimer said in a Wednesday note.

The report pointed to the potential for a meaningful uplift to revenue growth as its platform subscription pricing plan removes purchasing friction and drives multi-product adoption.

Other catalysts include favorable market dynamics and emerging opportunities in log management and security, the note added.

"Consensus projections are low, offering a high likelihood of growth re-rating and multiple expansion," the note said. "We see potential for an increase in valuation/multiples."

Oppenheimer initiated coverage on the stock with an outperform rating and a $65 price target.

Price: 49.61, Change: +1.50, Percent Change: +3.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Commerzbank Sees Bank of Canada Cutting Rates by 50bps Wednesday; Comments on The Currency
Commerzbank Sees Bank of Canada Cutting Rates by 50bps Wednesday; Comments on The Currency
Dec 11, 2024
07:55 AM EST, 12/11/2024 (MT Newswires) -- In line with the consensus, Commerzbank said it expects the Bank of Canada to cut interest rates another time by 50 basis points Wednesday to 3.25%. Canada's central bank is slated to release its policy statement at 9:45 a.m. ET Wednesday. The rate reduction estimate isn't only supported by the weak labor market,...
Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival
Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival
Dec 11, 2024
07:58 AM EST, 12/11/2024 (MT Newswires) -- Relay Therapeutics ( RLAY ) said Wednesday updated interim clinical data from its first-in-human study of RLY-2608 in combination with fulvestrant showed clinically meaningful progression-free survival in patients with locally advanced or metastatic breast cancer. The updated data showed a median progression-free survival of 11.4 months in second-line patients who received a 600-milligram...
OPEC again cuts 2024, 2025 oil demand growth forecasts
OPEC again cuts 2024, 2025 oil demand growth forecasts
Dec 11, 2024
LONDON (Reuters) -OPEC lowered its forecasts for 2024 and 2025 global oil demand growth on Wednesday in the fifth consecutive cut to the producers group's monthly report. The weaker outlook highlights the challenge facing OPEC+, which comprises the Organization of the Petroleum Exporting Countries and allies such as Russia. OPEC+ earlier this month delayed its plan to start raising output...
TeamViewer Agrees To Acquire Carlyle-Backed 1E For $720 Million: Details
TeamViewer Agrees To Acquire Carlyle-Backed 1E For $720 Million: Details
Dec 11, 2024
TeamViewer has entered an agreement with Carlyle Europe Technology Partners (CETP), part of the global investment firm Carlyle Group ( CG ) , to acquire 1E, a Digital Employee Experience (DEX) management tools company, for $720 million in a cash-free, debt-free deal. 1E, with around 300 employees, offers a leading DEX platform that boosts IT performance and employee satisfaction through...
Copyright 2023-2026 - www.financetom.com All Rights Reserved